Apellis Pharmaceuticals

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating disease through the inhibition of the complement system, which is a component of the immune system, at the level of C3, the central protein in the complement cascade. The company's clinical program targets C3 with Phase 3 clinical trials of its main product candidate, APL-2, in multiple indications. APL-2 has the potential to be a treatment that address the limitations of existing treatment options or provide a treatment option. The company is also conducting a Phase 2 trial of APL-2 in glomerular diseases, including C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy and lupus nephritis.
  • TickerAPLS
  • ISINUS03753U1060
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Closing of Previously Announced Exchanges of Approxi...

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). In the Exchange Transactions, the hold...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Agreements to Exchange Approximately $198.6 Million ...

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis ap...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration t...

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain WALTHAM, Mass. and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM) today an...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021 WALTHAM, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a Research and Development Day from 12:30 p.m. to 4:30 p.m. ET on Wednesday, June 30, 2021 in New York City and virtually. Apellis’ senior executive team will be joined by the following key opinion leaders at the event, which will feature a deep dive into the company’s growing pipeline in rare disease, ophthalmology, and neurology: Bruno Fattizzo...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Closing of Previously Announced Exchanges of Approxi...

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). In the Exchange Transactions, the hold...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Agreements to Exchange Approximately $198.6 Million ...

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis ap...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration t...

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain WALTHAM, Mass. and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM) today an...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021 WALTHAM, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a Research and Development Day from 12:30 p.m. to 4:30 p.m. ET on Wednesday, June 30, 2021 in New York City and virtually. Apellis’ senior executive team will be joined by the following key opinion leaders at the event, which will feature a deep dive into the company’s growing pipeline in rare disease, ophthalmology, and neurology: Bruno Fattizzo...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Closing of Previously Announced Exchanges of Approxi...

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). In the Exchange Transactions, the hold...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Agreements to Exchange Approximately $198.6 Million ...

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis ap...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration t...

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain WALTHAM, Mass. and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM) today an...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021 WALTHAM, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a Research and Development Day from 12:30 p.m. to 4:30 p.m. ET on Wednesday, June 30, 2021 in New York City and virtually. Apellis’ senior executive team will be joined by the following key opinion leaders at the event, which will feature a deep dive into the company’s growing pipeline in rare disease, ophthalmology, and neurology: Bruno Fattizzo...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Closing of Previously Announced Exchanges of Approxi...

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). In the Exchange Transactions, the hold...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Agreements to Exchange Approximately $198.6 Million ...

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis ap...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration t...

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain WALTHAM, Mass. and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM) today an...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021 WALTHAM, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a Research and Development Day from 12:30 p.m. to 4:30 p.m. ET on Wednesday, June 30, 2021 in New York City and virtually. Apellis’ senior executive team will be joined by the following key opinion leaders at the event, which will feature a deep dive into the company’s growing pipeline in rare disease, ophthalmology, and neurology: Bruno Fattizzo...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Closing of Previously Announced Exchanges of Approxi...

Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced the closing of its previously announced privately negotiated exchange transactions (the “Exchange Transactions”) with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). In the Exchange Transactions, the hold...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Announces Agreements to Exchange Approximately $198.6 Million ...

Apellis Announces Agreements to Exchange Approximately $198.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock WALTHAM, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.500% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of these exchange agreements, the holders have agreed to exchange with Apellis ap...

Laura Chico ... (+2)
  • Laura Chico
  • Kenneth Shields
 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration t...

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases Collaboration combines Apellis’ expertise in complement, a complex biological system, with Beam’s proprietary base editing platform Companies will collaborate on six research programs directed to tissues modulated by the complement system, including the eye, liver, and brain WALTHAM, Mass. and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM) today an...

 PRESS RELEASE
APLS Apellis Pharmac... (Health Care)

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021

Apellis Pharmaceuticals to Host R&D Day on June 30, 2021 WALTHAM, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a Research and Development Day from 12:30 p.m. to 4:30 p.m. ET on Wednesday, June 30, 2021 in New York City and virtually. Apellis’ senior executive team will be joined by the following key opinion leaders at the event, which will feature a deep dive into the company’s growing pipeline in rare disease, ophthalmology, and neurology: Bruno Fattizzo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch